New apabetalone publication out today in the journal Clinical Epigenetics. It contains much of the content and follows the theme of many of the posters that they have previously presented on this topic.

"Apabetalone (RVX-208) reduces vascular inflammation in vitro and in CVD patients by a BET-dependent epigenetic mechanism"

https://clinicalepigeneticsjournal.biomedcentral.com/articles/10.1186/s13148-019-0696-z

https://doi.org/10.1186/s13148-019-0696-z

On a side note about publications, in Mathias Haarhaus' ERA-EDTA slide presentation titled "The role of ALP as predictor of cardiovascular events and vascular calcification in CKD" he has a slide titled "Apabetalone inhibits ALP and improves cardiovascular risk" that shows data supporting that MACE incidence in the pooled apabetalone Phase 2's was related to on-treatement alkaline phosphatase levels. The bottom of the slide indicates "Haarhaus et al. Manuscript under review."

BearDownAZ